Berlan Michel, Verhaeghe Stephan, Pavy-Le Traon Anne, Thalamas Claire, Lafontan Max, Marques Marie Adeline, Senard Jean Michel, Parent Marc, Galitzky Jean
Pharmacologie Medical and Clinical Laboratory, INSERM U-317, Paul Sabatier University, Toulouse, France.
Aviat Space Environ Med. 2002 Aug;73(8):735-42.
Simulated microgravity produces sustained inhibition of sympathoneural release, turnover, and synthesis of norepinephrine (NE) and hypersensitization of beta-adrenergic pathways. These changes may explain the orthostatic intolerance experienced by astronauts returning from spaceflights.
Chronic administration of yohimbine would prevent the increase of beta-adrenergic hypersensitivity to epinephrine (Epi) induced by simulated microgravity.
Eight healthy young subjects received 8 mg of yohimbine (an antagonist of alpha2adrenoceptors) orally twice a day during the simulated microgravity achieved through -6 degrees head-down bed rest (HDBR). The catecholamine-induced lipolysis was studied on isolated fat cells from subcutaneous adipose tissue before HDBR and on the fifth day of HDBR. Epi was infused at three graded rates (0.01, 0.02, and 0.03 microg x kg(-1) x min(-1) for 40 min each) before and at the end of the HDBR period. The effects of Epi on the sympathetic nervous system (SNS) activity-assessed by plasma NE levels and spectral analysis of systolic BP and heart rate variability-and on plasma levels of glycerol, non-esterified fatty acids, glucose, and insulin and on energy expenditure were evaluated.
Under yohimbine treatment, HDBR failed to modify urinary NE excretion and spectral variability of systolic BP in the mid-frequency range. The beta- and alpha-adrenergic sensitivity of fat cells were not modified by HDBR nor were plasma NE levels and spectral variability of systolic BP induced by Epi infusion. No alteration of Epi-induced changes in heart rate and systolic and diastolic BPs were observed after HDBR. Epi-induced increases in plasma glucose, insulin, glycerol, and non-esterified fatty acid levels as well as energy expenditure were also unmodified by HDBR. Only the Epi-induced plasma lactate level was increased by HDBR.
Our data suggest that the increase in the effects of Epi induced during microgravity could be attenuated by chronic administration of yohimbine. An explanation for this effect could be SNS activation brought about by the alpha2-adrenoceptor antagonist properties of yohimbine.
模拟微重力会持续抑制交感神经释放、去甲肾上腺素(NE)的周转和合成,并使β-肾上腺素能途径超敏化。这些变化可能解释了从太空飞行返回的宇航员所经历的体位性不耐受。
长期给予育亨宾可预防模拟微重力诱导的β-肾上腺素能对肾上腺素(Epi)超敏性的增加。
八名健康年轻受试者在通过 -6 度头低位卧床休息(HDBR)实现模拟微重力期间,每天口服两次 8 毫克育亨宾(一种α2肾上腺素能受体拮抗剂)。在 HDBR 前和 HDBR 的第五天,对来自皮下脂肪组织的分离脂肪细胞进行儿茶酚胺诱导的脂肪分解研究。在 HDBR 期开始前和结束时,以三种分级速率(分别为 0.01、0.02 和 0.03 微克×千克-1×分钟-1,每次 40 分钟)输注 Epi。评估 Epi 对交感神经系统(SNS)活动(通过血浆 NE 水平以及收缩压和心率变异性的频谱分析评估)、血浆甘油、非酯化脂肪酸、葡萄糖和胰岛素水平以及能量消耗的影响。
在育亨宾治疗下,HDBR 未能改变尿 NE 排泄以及中频段收缩压的频谱变异性。HDBR 未改变脂肪细胞的β-和α-肾上腺素能敏感性,Epi 输注诱导的血浆 NE 水平和收缩压频谱变异性也未改变。HDBR 后未观察到 Epi 诱导的心率以及收缩压和舒张压变化的改变。Epi 诱导的血浆葡萄糖、胰岛素、甘油和非酯化脂肪酸水平以及能量消耗的增加也未因 HDBR 而改变。只有 Epi 诱导的血浆乳酸水平因 HDBR 而升高。
我们的数据表明,长期给予育亨宾可减轻微重力期间诱导的 Epi 作用的增加。对此效应的一种解释可能是育亨宾的α2肾上腺素能受体拮抗剂特性引起的 SNS 激活。